Same ivermectin that US government doesn’t want Americans

New Post Public Reply Private Reply Replies (0) Message Board
energy_wave copytele #69697
228
Same ivermectin that US government doesn’t want Americans to receive is saving lives across India

India-Vaccine-Pills-Drugs-Map.jpg

Quote:
Uttar Pradesh, one of India’s most densely populated regions, is doing exceptionally well with the Wuhan coronavirus (Covid-19) “cases.” The reason why? Ivermectin is widely used there.

With a population of 240 million people, which is about 75 percent of the total United States population, Uttar Pradesh has had only about 24 cases of the Chinese Virus and no deaths over the past several months. This is astounding compared to what is happening throughout the West.

Among India’s 36 states, Uttar Pradesh boasts being dead last on the list of infected states. Once again, the reason for this is simple: ivermectin is not a dirty word there like it is in the U.S.

“Evidently, the global medical junta doesn’t like the over 60 studies vouching for the efficacy of ivermectin against SARS-CoV-2, especially when used early, but there is something better than a study: pure reality of lived experience,” writes Daniel Horowitz for Blaze Media.

Beginning in late 2020, authorities in Uttar Pradesh began liberally dispensing ivermectin to people, urging them to take it early on at the first signs of a possible infection and even preventatively. This advice turned out to be solid.

“By the end of 2020, Uttar Pradesh – which distributed free ivermectin for home care – had the second-lowest fatality rate in India at 0.26 per 100,000 residents in December. Only the state of Bihar, with 128 million residents, was lower, and it, too, recommends ivermectin,” reported Trial Site News.

For a “horse de-wormer,” ivermectin sure did help Uttar Pradesh avoid a major crisis. Ever since the drug was introduced there, the Fauci Flu has pretty much been eradicated.

Nobody is dying from Chinese Germs there because they are gaining protection from the use of ivermectin, which has repeatedly been shown as effective against the Wuhan Flu.

“Uttar Pradesh likely would have been the first world experiment of what a given area would have looked like had they been taking ivermectin from day one before a wave hit,” Horowitz explains.

“Unfortunately, hundreds of thousands of seasonal migrants fled Mumbai and other big cities when the Delta wave hit and all settled back in their villages in Uttar Pradesh, giving them the same spike that every other state got because those people were not on ivermectin.”

As of now, there has still not been a proper case study using an actual population like this to demonstrate the power of ivermectin to put an end to the plandemic.

This is unfortunate because we could have been long done with this nonsense ages ago, were it not for the corrupt political influence that is keeping ivermectin out of the hands of the people, particularly in the West.

There would be no need for panic, masks, “vaccines,” or any other mindless hysteria if the “authorities” would just give up their crusade against ivermectin and let people try it. Many deaths and hospitalization could be prevented this way.

Tony Fauci and his cronies continue to try to strongarm India into accepting snake oil “remedies” like remdesivir and Donald “father of the vaccine” Trump’s “Operation Warp Speed” injections, but the country, or at least parts of it, have been resisting rather formidably.

“All trials are saying that this drug is not effective in the treatment of COVID-19, rather it is complicating and resulting in mortality of patients,” says Dr. Surya Kant Tripathi about the failure of remdesivir.

“At so many centers, remdesivir trials were stopped. Also, remdesivir is costing minimum of Rs 5,000 per vial.”

The latest news about the Wuhan coronavirus (Covid-19) plandemic can be found at Pandemic.news.

Sources for this article include:

TheBlaze.com

NaturalNews.com


https://www.newstarget.com/2021-09-17-ivermec...india.html
big-wave_surfing_01.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Fox Factory Stock Hits Record Low with Strategic Adjustments

Updated Category News Views 104

Market Challenges and Stock Performance Fox Factory Holding Corp (NASDAQ: FOXF) has recently seen its stock sink to a 52-week low, reaching $28.92. This downturn reflects the challenging market conditions the company is currently facing. With a market capitalization of $1.2 billion and a price-to-earnings (P/E) ratio of 113, FOXF now trades below its fair value. Over the...

Continue Reading
Entropy Robotics Partners with SRI for Innovative Navigation

Updated Category News Views 205

Entropy Robotics Partners with SRI for Innovative Navigation Entropy Robotics, an innovative startup focused on AI-driven solutions for robotics and drones, has recently formed a strategic partnership with SRI, an independent nonprofit research organization. This collaboration aims to enhance autonomous navigation capabilities for robots operating in challenging...

Continue Reading
Legal Opportunities for Quanex Building Products Investors

Updated Category News Views 130

Investment Legal Options for Quanex Building Products Corporation Bronstein, Gewirtz & Grossman, LLC, a leading law firm in investor representation, has announced a significant opportunity for shareholders of Quanex Building Products Corporation (NYSE: NX). Investors who have incurred considerable losses are being invited to participate and potentially lead a class action...

Continue Reading
Braskem Launches Sustainable Bio-Circular Polypropylene for Food Industry

Updated Category News Views 82

Braskem's Innovative Sustainability Effort Braskem (B3: BRKM3, BRKM5, and BRKM6; NYSE: BAK) has launched an exciting new sustainable product—bio-circular polypropylene (PP), known as WENEW. As the top producer of polyolefins in the Americas, Braskem is raising the bar by offering this eco-friendly solution specifically designed for the restaurant and snack food...

Continue Reading
Exploring the Growth of Direxion Daily Semiconductor Shares

Updated Category News Views 136

Understanding Direxion Daily Semiconductor Bull 3X Shares Direxion Daily Semiconductor Bull 3X Shares (NYSE: SOXL) has delivered impressive returns over the past 15 years, outperforming the general market by a remarkable 29.99% on an annualized basis. The fund boasts an average annual return of 41.86%, showcasing its strength in the technology sector, which continues to...

Continue Reading